Treatment Information


Ovarian Cancer treatment details. Chemotherapy, Surgery.

Institut Paoli-Calmettes, Marseille, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Marseille
Treatments:Chemotherapy, SurgeryHospital:Institut Paoli-Calmettes
Date:Apr 2006


Patients: This phase II study involved thirty four patients (median age=50 years) with stage IIIc or IV epithelial ovarian cancer.

Treatment: The treatment consisted of post-operative high-dose chemotherapy with haematopoietic stem cell support. Patients received a post-operative sequential combination of high-dose cyclophosphamide/epirubicin with haematopoietic stem cell harvesting, high-dose carboplatin followed by haematopoietic stem cell infusion, and dose-dense paclitaxel. Rh-G-CSF (filgrastim) was administered following all cycles.

Toxicity: Hematological toxicuty was reported as "severe" and febrile neutropenia requiring hospitalization was experienced by about 75% of patients. In addition, three patients withdrew from the study due to the toxicities they experienced, which included sepsis, inadequate platelet count, pneumonia and reversible grade 3 central neurological alterations that included confusion.

Results: Median overall survival was not reported, but the estimated 5-year overall survival was reported as 40%. The authors concluded that the observed response rate "does not support a clear advantage (of this protocol) over conventional treatment."

Correspondence: Dr. A. Goncalves